Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.

about

Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.

Item

http://www.wikidata.org/entity/Q50036781

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@en

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@nl

type

Item

label

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@en

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@nl

prefLabel

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@en

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@nl

P1476

Hydroxychloroquine: A Physiolo ...... -Related Autophagy Modulation.

@en

P2093

Daniel L Gustafson

http://www.w3.org/2001/XMLSchema#string

Keagan P Collins

http://www.w3.org/2001/XMLSchema#string

Kristen M Jackson

http://www.w3.org/2001/XMLSchema#string

P2860

Quantitative modeling of selective lysosomal targeting for drug design

Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system

Reprint of PopGen: A virtual human population generator.

Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.

Prediction of hepatic clearance in human from in vitro data for successful drug development.

Lysosomes revisited.

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.

P31

scholarly article

P356

10.1124/JPET.117.245639

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29438998

http://www.w3.org/2001/XMLSchema#string

P921

hydroxychloroquine

P932

5931434

http://www.w3.org/2001/XMLSchema#string